<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82949">
  <stage>Registered</stage>
  <submitdate>1/07/2008</submitdate>
  <approvaldate>30/09/2008</approvaldate>
  <actrnumber>ACTRN12608000498392</actrnumber>
  <trial_identification>
    <studytitle>The role of glucoregulatory processes in the cognition-enhancing effects of selected botanicals in healthy adults</studytitle>
    <scientifictitle>The role of glucoregulatory processes in the cognition-enhancing effects of selected botanicals in healthy adults</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>cognitive function</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Study 1: The study will involve an oral administration of 3 Panax aquinquefolius  doses (100mg, 200mg and 400mg)
On each testing day, participants will be randomly allocated to take a treatment once immediately after baseline assessment. Following a one week washout period each volunteer will return to the testing labs an undergo the same procedure under a different dose of Panax aquinquefolius until all treatments are complete.
Study 2: The methodology will be identical to that described in study 1, except three doses of Fraxinus excelsior (200mg, 400mg and 600mg) will be used. 
Study 3: The methodology will be identical to that described in study 1, except three doses of Rosmarinus officinalis (250mg, 500mg and 750mg) will be used. 
Study 4: The methodology will be identical to that described in study 1, except three doses of Spergularea purpurea (200mg, 400mg and 600mg) will be used. 
Study 5: The methodology will be similar to the previous studies except that it will compare the optimal doses for cognitive enhancement identified in the preceding studies.</interventions>
    <comparator>Participants will take a placebo capsule containing maltidextrin immediately following baseline testing.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cognitive function (working memory, secondary memory, attention and executive function) as measured by the Computerised Mental Performance Assessment (COMPASS)</outcome>
      <timepoint>Baseline and at 1, 3 and 6 hours post treatment administration</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Blood Glucose Levels</outcome>
      <timepoint>Baseline and at 1, 3 and 6 hours post treatment administration</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective mood measures using the Bond Lader Visual Analogue Scales</outcome>
      <timepoint>At baseline and at 1, 3 and 6 hours post treatment administration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anxiety as measured by the State Trait Anxiety Inventory (STAI)</outcome>
      <timepoint>Baseline and at 1, 3 and 6 hours post treatment administration</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>non-smoker, 
no history of anxiety, depression or psychiatric disorders
not taking medication (prescription or over the counter), herbal extracts, vitamin supplements or illicit drugs
no kidney disease, liver disease and/or gastrointestinal diseases (e.g. Irritable bowel syndrome, celiac disease, peptic ulcers)
no health conditions affecting blood glucose levels - Diabetes (Type 1 &amp; 2), hypoglycaemia, hyperglycaemia
no health conditions affecting the adrenal glands - Cushing's disease, Addison's disease
not pregnant or breast feeding.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>smoker
history of anxiety, depression or psychiatric disorders
taking any medication (prescription or over the counter), herbal extracts, vitamin supplements or illicit drugs
food allergies, kidney disease, liver disease and/or gastrointestinal diseases (e.g. Irritable bowel syndrome, celiac disease, peptic ulcers)
health conditions affecting blood glucose levels - Diabetes (Type 1 &amp; 2), hypoglycaemia, hyperglycaemia
health conditions affecting the adrenal glands - Cushing's disease, Addison's disease
pregnant or breast feeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Simple randomisation using latin square to ensure a fully counterbalanced design. 

Allocation concealment via central randomisation (computer)</concealment>
    <sequence>Simple randomisation using latin square</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>17/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Swinburne University of Technology</primarysponsorname>
    <primarysponsoraddress>PO Box 218
HAWTHORN VIC 3122</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Naturex</fundingname>
      <fundingaddress>375 Huyler Street
South Hackensack, NJ 07606</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aims of this study are to:

1) establish the extent to which extracts with glucoregulatory properties can improve mood and cognitive performance, 
2) establish the optimum cognition-enhancing dose for each extract
3) determine which cognitive domains are most affected by each extract
4) examine the effects of each extract on glucose levels and cognitive function
5) examine the effect of each extract on glucose control in relation to cognitive function 
6) directly compare the neurocognitive effects of optimum doses of the extracts examined in the trial</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Swinburne University Human Research Ethics Committee (SUHREC)</ethicname>
      <ethicaddress>Swinburne University of Technology
P O Box 218
HAWTHORN VIC 3122</ethicaddress>
      <ethicapprovaldate>16/04/2008</ethicapprovaldate>
      <hrec>SUHREC Project 0708/155</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Andrew Scholey</name>
      <address>Swinburne University of Technology
P O Box 218
HAWTHORN VIC 3122</address>
      <phone>+ 61 39214 8932</phone>
      <fax>+ 61 39214 5525</fax>
      <email>ascholey@swin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Andrew Scholey</name>
      <address>Swinburne University of Technology
P O Box 218
HAWTHORN VIC 3122</address>
      <phone>+ 61 39214 8932</phone>
      <fax>+ 61 39214 5525</fax>
      <email>ascholey@swin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Christina Kure</name>
      <address>Swinburne University of Technology
P O Box 218
HAWTHORN VIC 3122</address>
      <phone>+ 61 39214 4476</phone>
      <fax>+ 61 39214 5525</fax>
      <email>ckure@swin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>